Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in korean patients with acute coronary syndrome

Korean Journal of Laboratory Medicine

Volumn 31, Issue 2, 2011, Pages 91-94

  Park, Kyoung Jin ^a   Chung, Hae Sun ^b   Kim, Suk Ran ^a   Kim, Hee Jin ^a   Han, Ju Yong ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Acute coronary syndrome; Clopidogrel resistance; CYP2C19; Korean; Platelet inhibition

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASIAN; BLOOD; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; SOUTH KOREA;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES COMPLICATIONS; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA; TICLOPIDINE;

EID: 79955369135     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2011.31.2.91     Document Type: Article

References (14)

1. Gurbel PA, Antonino MJ, Tantry US. Recent developments in Clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009;5:989-1004.
2. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010,56:112-6.
3. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, at al. Adjusted Clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with Clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11.
4. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34.
5. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to Clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
6. Angiolillo DJ and Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007;98:707-9. (Pubitemid 47555058)
7. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, at al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic Clopidogrel therapy. J Thromb Haemost 2010;8:1685-93.
8. Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, at al. Relation of genetic polymorphisms in the cytochrome P450 gene with Clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009;104:46-51.
9. Collet JP, Hulot JS, Pena A, VTllard E, Esteve JB, Silvain J, at al. Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
10. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of Clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93:456-8.
11. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, BarreraRamirez C, Sabaté M, et al. Identification of low responders to a 300-mg Clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-8. (Pubitemid 39572762)
12. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8. (Pubitemid 24334747)
13. Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. Which platelet function test is suitable to monitor Clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogreL J Thromb Haemost 2010;8:482-8.
14. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of Clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 2008;48:1219-24.